Reproductive startup launches test to identify an embryo's genetic defects before an IVF pregnancy begins
Publishing timestamp: 2023-12-05 09:00:01
Summary
Orchid, a reproductive technology startup, has launched the first commercially available whole genome sequencing test for embryos. This test can identify birth defects, neurodevelopmental disorders, chromosomal abnormalities, and pediatric and adult-onset cancers before pregnancy begins. The technology is designed for couples undergoing in vitro fertilization (IVF) and provides them with more control and confidence in the process. The test sequences more than 99% of the embryo's genome and will cost couples an additional $2500 per embryo sequenced. Orchid's technology will be available at IVF clinics in major cities, and couples will receive their report back after about three weeks. The company has secured $12 million in funding and has the support of prominent investors. The launch of this test has the potential to redefine reproduction and provide hopeful parents with peace of mind.
Sentiment: POSITIVE
Keywords: health care industry, technology, breaking news: business, start-up, breaking news: technology, enterprise, 23andme holding co., instacart (maplebear inc), coinbase global inc, internet, sexual and reproductive health, business news,